drugset / Trial / NCT07539233
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of QI-019B in patients with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2026-04-15
- Primary completion
- 2028-08-01
- Completion
- 2029-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QI-019B | Unknown | — | — |